Author: sf-admin

The data-center build-out is being financed with record borrowing, much of it private. A former Treasury and Pentagon advisor traces where that risk ultimately lands.

The data-center build-out is being financed with record borrowing, much of it private. A former Treasury and Pentagon advisor traces where that risk ultimately lands.

Pricing of CNH Industrial Capital LLC $600 million notes

New York, NY, June 22, 2026 (GLOBE NEWSWIRE) — Wilco 63 Corporation (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on June 18, 2026 on The Nasdaq Global Stock Market LLC (“Nasdaq”) under the ticker symbol “WLCOU.” Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “WLCO” and “WLCOW,” respectively. Of the proceeds received from the consummation of the initial public offering (including the exercise of the over-allotment option) and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in trust.

2026 haul is most in statewide public TV network’s history

2026 haul is most in statewide public TV network’s history

Southfield, MI, June 22, 2026 (GLOBE NEWSWIRE) — Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities (collectively, the “properties”), today announced the appointment of Ileana McAlary as General Counsel, Executive Vice President, and Secretary, effective June 29, 2026.

NEW YORK, NY, June 22, 2026 (GLOBE NEWSWIRE) — Texas Ventures Acquisition IV Corp (the “Company”) announced today the closing of its initial public offering of 17,250,000 units, which includes 2,250,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $172,500,000.

LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET.

DALLAS, June 22, 2026 (GLOBE NEWSWIRE) — Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost” or “Ridgepost Capital”) today announced it has completed its previously announced acquisition of Stellus Capital Management, LLC (“Stellus”), a leading U.S. direct lender focused on the lower-middle market with approximately $4 billion in assets under management. Stellus will continue to be managed by its current partners who will lead day-to-day operations, including investment decisions and investment committee processes.

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).

QuantRate Launches Free AI Trading Bot to Transform Automated Investing Across Crypto and Stock Markets

North Park biology students placed first and third at the TriBeta NC-1 District Research Conference.

North Park biology students placed first and third at the TriBeta NC-1 District Research Conference.

Growth creates high-paying defense and space tech jobs

Growth creates high-paying defense and space tech jobs

A widely cited MIT study found almost no measurable corporate profits from generative AI so far. A former Pentagon and CIA advisor puts that finding next to the valuations investors are paying.

A widely cited MIT study found almost no measurable corporate profits from generative AI so far. A former Pentagon and CIA advisor puts that finding next to the valuations investors are paying.

New nonprofit research and development lab brings together a group of senior technical contributors from the Ethereum Foundation to ready the network for step-function wave of adoption from institutions, agentic finance and DeFi

Fortrade Expands Its Instrument Range With New Shares Across AI, Networking, Space, and Advanced Materials

The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologics, along with ongoing clinical research, is expanding the treatment landscape for CLE patients.

The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologics, along with ongoing clinical research, is expanding the treatment landscape for CLE patients.